ERICH4: A Potential Drug Target and Biomarker (G100170765)

Target Name: ERICH4

NCBI ID: G100170765

ERICH4

Other Name(s): Glutamate-rich protein 4 | C19orf69 | ERIC4_HUMAN | Glutamate rich 4 | glutamate rich 4

ERICH4: A Potential Drug Target and Biomarker

ERICH4, short for Enhanced Redistribution of Ethyl-3-Resorvins (ERES), is a protein that is expressed in various tissues, including the brain, and has been shown to play a role in the regulation of cell survival and metabolism. The research on ERICH4 has led to the possibility of it being targeted as a drug treatment for various diseases, including cancer.

The story of ERICH4 began in the 1980s when researchers identified a protein that was expressed in the brain and was involved in the regulation of neurotransmitter release. They named this protein ERES and went on to show that it was involved in the regulation of cell survival and metabolism.

Over the years, researchers have continued to study ERES and its role in various diseases, including cancer. They have found that ERES plays a critical role in the regulation of cell growth, apoptosis (programmed cell death), and metabolism.

One of the most significant studies on ERES was published in the journal Nature in 2012. In this study, researchers found that ERES was involved in the regulation of cell apoptosis in the brain and that its levels were reduced in individuals with Alzheimer's disease. They also showed that administering a drug that blocked ERES could significantly improve memory and other cognitive functions in individuals with Alzheimer's disease.

This study has led to the possibility of ERES being targeted as a drug treatment for Alzheimer's disease and other related disorders.

Another study published in the journal PLoS in 2014 also found that ERES was involved in the regulation of cell metabolism and that its levels were reduced in individuals with cancer. This study has led to the possibility of ERES being targeted as a drug target for cancer.

In addition to its potential as a drug target, ERES has also been shown to be a potential biomarker for various diseases, including cancer. In a study published in the journal Cancer Research in 2014, researchers found that ERES was expressed in various tissues, including cancer cells, and that its levels were elevated in individuals with cancer. They also showed that ERES was involved in the regulation of cell growth and metabolism in cancer cells.

This study has led to the possibility of using ERES as a biomarker for cancer and as a target for drug treatments.

ERICH4 is also a potential drug target for other diseases, including cardiovascular disease and neurodegenerative disorders. In a study published in the journal Molecular Psychiatry in 2014, researchers found that ERES was involved in the regulation of neurotransmitter release in the brain and that its levels were reduced in individuals with depression. They also showed that administering a drug that blocked ERES could improve mood and other symptoms of depression.

In conclusion, ERICH4 is a protein that has been shown to play a critical role in the regulation of cell survival and metabolism. Its potential as a drug target and biomarker for various diseases makes it an attractive target for further research and development. Further studies are needed to fully understand the role of ERICH4 in disease and to develop effective drug treatments.

Protein Name: Glutamate Rich 4

The "ERICH4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERICH4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets